A tau PET scan, a brain imaging test that makes tau tangles visible, fits after Alzheimer pathology is confirmed to show stage rather than to make the first diagnosis. Amyloid testing usually answers whether Alzheimer changes are present, while tau imaging shows how widely tangles have spread. According to the National Institute on Aging diagnostic guidelines, a full workup starts with medical history, memory and language testing, routine blood and urine tests, and CT or MRI. Spinal fluid or PET biomarkers then add support for the diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the basic workup cover?
- Which result establishes Alzheimer's disease?
- What does tau PET add after presence is known?
- What are the limits and practical next steps?
What does the basic workup cover?
The first visit focuses on history and function. The clinician asks about symptoms, daily abilities, and medications, then tests memory, language, and thinking skills.
Routine blood and urine tests look for other causes of confusion. A structural CT or MRI checks for stroke, tumor, fluid buildup, or pronounced shrinkage.
Which result establishes Alzheimer's disease?
Alzheimer's is now defined biologically, not by symptoms alone. According to the 2024 Alzheimer's Association Workgroup criteria, one abnormal Core 1 biomarker establishes the disease, including amyloid PET, approved spinal fluid assays, or accurate plasma tests especially p-tau217.
Amyloid PET is often the test that answers presence. Eli Lilly's Amyvid information says it estimates neuritic plaque density to evaluate cognitive impairment and select patients for amyloid-directed therapy.
What does tau PET add after presence is known?
Tau PET estimates the density and spread of tau neurofibrillary tangles in adults with cognitive impairment evaluated for Alzheimer's. The first FDA-approved tracer was Tauvid in May 2020, and NeurologyLive reported a second tracer, Tauklarify, in August 2026.
According to the 2025 Association and SNMMI criteria in the Journal of Nuclear Medicine, tau PET adds staging after pathology is established because neocortical tau spread tracks clinical severity. The criteria rate 17 clinical scenarios for amyloid and tau PET separately, keeping presence and staging as distinct jobs.
What are the limits and practical next steps?
Tau PET has clear limits that families should know. According to the DailyMed Tauvid label, it is not indicated for chronic traumatic encephalopathy, a negative scan needs added evaluation to exclude Alzheimer pathology, and small noncontiguous uptake foci can cause false positives.
Blood tests such as Lumipulse G pTau217 and beta-amyloid 1-42 can aid detection of amyloid pathology but are not standalone diagnoses. The Being Patient summary of FDA reporting notes equivocal cases still proceed to amyloid or tau PET or spinal fluid testing. Small noncontiguous spots of tracer uptake can mimic meaningful tau, so expert reading matters.
- Ask whether amyloid status is already established before tau PET.
- Ask who will read the scan and how spread will be explained.
- Bring prior CT, MRI, lab results, and a list of daily changes.





